US Pharm. 2013;38(6):18.
Irvine, CA—Researchers at the University of California, Irvine (UC Irvine), have created a way to clearly identify clinically usable markers for prostate cancer in urine. The new test detects prostate-specific membrane antigen (PSMA), a different biomarker from what is currently identified in the prostate-specific antigen (PSA) test, which does not always catch the cancer in its early stages and may yield false positives. The new method has already been patented and licensed, and human clinical trials are the next step. The goal is for early screening for prostate cancer to become as easy, accurate, and affordable for men as home pregnancy testing is for women.
To comment on this article, contact rdavidson@uspharmacist.com.
